Author:
Fallah Mohammad,Mosayebi Mahdi,Matini Mohammad,Darabi Fateme, , , ,
Reference25 articles.
1. Polat ZA, Cetin A, Savage PB. Evaluation of the in vitro activity of ceragenins against Trichomonas vaginalis. Acta Parasitol. 2016;61(2):376-81.
2. Orozco E, Marchat LA, Gómez C, López-Camarillo C, Pérez DG. Drug resistance mechanisms in Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, and opportunistic anaerobic protozoa. Antimicrobial drug resistance: Springer; 2009. p. 549-59.
3. Karimi FZ, Bakhshi M, Dadgar S, Maleki-Saghooni N. Review of anti-Trichomonas vaginalis herbs and their therapeutic effects. Iran. J. Obstet. Gynecol. Infertil. 2018;20(12):96-109.
4. Küng E, Fürnkranz U, Walochnik J. Chemotherapeutic options for the treatment of human trichomoniasis. Int J Antimicrob Agents. 2019;53(2):116-27.
5. Ali V, Nozaki T. Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by “amitochondriate” protozoan parasites. Clin Microbiol Rev. 2007;20(1):164-87.